Abstracts Archive - Page 2592 of 2607 - ACR Meeting Abstracts

Abstract Number: 185 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet’s Disease with Uveitis As Main Involvement
M. Victoria Hernández¹, Marina Mesquida², Gerard Espinosa³, Victor Llorens², Laura Pelegrin², Juan D. Cañete⁴, Ricard Cervera⁵, Alfredo M. Adan² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ³Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁵Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: To assess the long-term efficacy and safety of tumour necrosis factor (TNF) antagonists (infliximab [IFX], adalimumab [ADA] and golimumab) for the treatment of patients…
Abstract Number: 186 • 2012 ACR/ARHP Annual Meeting
Long-Term Infliximab Therapy in Patients with Behcet’s Disease Is Well Tolerated without Increasing Risk of Serious Infections
Sho Ueda, Hiroshi Tsukamoto, Yasushi Inoue, Masahiro Ayano, Satomi Hisamoto, Naoko Ueki, Atsushi Tanaka, Shun-ichiro Ohta, Naoyasu Ueda, Yojiro Arinobu, Hiroaki Niiro, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Infliximab (IFX) is a monoclonal antibody against tumor necrosis factor-a (TNF-a) and is increasingly used in various immune-related diseases including rheumatoid arthritis (RA), ankylosing…
Abstract Number: 147 • 2012 ACR/ARHP Annual Meeting
Improvements in Long-Term Health-Related Quality of Life in Chronic Gout Patients Refractory to Conventional Therapies Treated with Pegloticase: Results From Responder Cohort
Dinesh Khanna¹, Puja Khanna² and Faith D. Ottery³, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ
Background/Purpose: In replicate, 6-month, randomized, placebo-controlled Phase 3 clinical trials a subgroup of patients with treatment-refractory chronic gout (RCG) who received pegloticase infusions (8 mg)…
Abstract Number: 148 • 2012 ACR/ARHP Annual Meeting
Towards a Preliminary Definition of Remission From Gout
William Taylor¹, Nicola Dalbeth², Jasvinder A. Singh³, Kenneth G. Saag⁴ and H. R. Schumacher⁵, ¹University of Otago, Wellington, New Zealand, ²Medicine, University of Auckland, Auckland, New Zealand, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁵Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: There is currently no agreed criterion for remission in chronic gout. The aim of this study was to develop a preliminary definition for remission…
Abstract Number: 149 • 2012 ACR/ARHP Annual Meeting
Natural Language Processing in the Evaluation of Gout Quality Indicators
Gail S. Kerr¹, J. Steuart Richards², Carl A. Nunziato³, Olga V. Patterson⁴, Scott L. DuVall⁵, David D. Maron⁶ and Richard L. Amdur⁷, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ³Rheumatology, Washington DC VA and Howard University, Washington, DC, ⁴VA Salt Lake City Health Care System and University of Utah School of Medicine, UT, ⁵VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁶Research Department, Washington DC VA Medical Center, Washington, DC, ⁷Washington DC VA and Georgetown Unviversity, Washington, DC
Background/Purpose: Gout is a common inflammatory arthritis with significant impact on both patients and health care systems. Despite ACR/EULAR management guidelines and gout quality indicators…
Abstract Number: 150 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study
Alan S. Hollister¹, Andreas Maetzel¹, Michael A. Becker², Robert Terkeltaub³, David Fitz-Patrick⁴, Valerie Smith⁵ and William P. Sheridan⁶, ¹Development, BioCryst Pharmaceuticals, Inc., Durham, NC, ²Medicine, University of Chicago, Chicago, IL, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴East-West Medical Research Institute, Honolulu, HI, ⁵Pharpoint Research, Inc., Durham, NC, ⁶BioCryst Pharmaceuticals, Inc., Durham, NC
Background/Purpose: A majority of gout patients treated with 300 mg/d allopurinol do not reach the therapeutic goal range serum uric acid concentration (sUA) of 4…
Abstract Number: 151 • 2012 ACR/ARHP Annual Meeting
Management of Gout Attacks in the Community
Tuhina Neogi¹, Clara Chen², Christine E. Chaisson², David J. Hunter³, Hyon Choi⁴ and Yuqing Zhang⁵, ¹Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁴Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: We previously examined management of gout attacks in the community in 2003-4. Since then, new agents have become available and gout publications have increased,…
Abstract Number: 152 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)
Robert R. Evans¹, Steven P. Weinstein², George D. Yancopoulos³ and Yuhwen Soo⁴, ¹Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Research Labs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Two similarly designed phase 3 randomized clinical trials (PRESURGE-1 and PRESURGE-2) in gout patients initiating urate-lowering therapy (ULT) showed that subcutaneous treatment with the…
Abstract Number: 153 • 2012 ACR/ARHP Annual Meeting
Prevention of Recurrent Calcium Stones in Subjects with Hyperuricosuria: A Randomized Controlled Trial of Febuxostat Vs Allopurinol
David S. Goldfarb¹, Patricia A. MacDonald², Lhanoo Gunawardhana³, Solomon Chefo³ and Lachy McLean⁴, ¹New York Universtiy Langone Medical Center, New York, NY, ²Takeda Pharmaceuticals USA, Inc., Deerfield, IL, ³Takeda Global Research & Development Center, Inc., Deerfield, IL, ⁴Takeda Global Research & Development Center, Inc, Deerfield, IL
Background/Purpose: About one-third of patients with recurrent calcium oxalate (CaOx) stones have hyperuricosuria as a urinary risk factor. Febuxostat (FEB), a newer xanthine oxidase inhibitor…
Abstract Number: 154 • 2012 ACR/ARHP Annual Meeting
Dual-Energy Computed Tomography As a Diagnostic Tool for Gout During Intercritical Periods
Gabriel S. Breuer¹, Naama Bogot² and Gideon Nesher³, ¹Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ²Radiology, Shaare Zedek Medical Center p o box 3235 Jerusalem, Israel, Israel, ³Internal Medicine, Shaare Zedek Medical Center, Jerusalem, Israel
Background/Purpose: Dual-energy computed tomography (DECT) is a sensitive method for identifying uric acid deposits in joints and periarticular soft tissues in patients suspected of having…
Abstract Number: 155 • 2012 ACR/ARHP Annual Meeting
Accuracy of International Classification of Disease Codes for Calcium Pyrophosphate Disease in the Veterans Adminstration Healthcare System
Karri A. Huber¹, Lawrence M. Ryan² and Ann K. Rosenthal³, ¹Rheumatology, MCW Froedtert Hospital, Milwaukee, WI, ²Department of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Calcium pyrophosphate disease (CPPD) commonly affects elderly patients, but few advances in our management of this disease have occurred in the 50 years since…
Abstract Number: 156 • 2012 ACR/ARHP Annual Meeting
Menopause and the Prevalence of Gout and Hyperuricemia: An Age-Matched Case Control Study
Eswar Krishnan¹ and Mihoko Bennett², ¹Medicine, Standford University, Palo Alto, CA, ²Pediatrics, Stanford University, Palo Alto, CA
Background/Purpose: Among women, the prevalence of gouty arthritis (gout) and hyperuricemia (serum urate>6.0 mg/dL) increases steeply after the age 60. This increase has been attributed…
Abstract Number: 157 • 2012 ACR/ARHP Annual Meeting
Prevalence of Gout Among Adults with Chronic Kidney Disease in the United States, 2009-10
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is a major route of clearance of uric acid, a product of purine metabolism. The links between kidney disease, hyperuricemia, and gout…
Abstract Number: 158 • 2012 ACR/ARHP Annual Meeting
Focus Groups Reveal Knowledge Gaps in Patients with Gout-A Qualitative Study
Puja Khanna¹, Veronica Berrocal², Tonya Hays³, Daniel J. Clauw⁴ and David A. Williams⁵, ¹Division of Rheumatology/Dept. of Internal Medicine, University of Michigan, Ann Arbor, MI, ²Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, ³Survey Research Center, UCLA, Los Angeles, CA, ⁴Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁵Chronic Pain & Fatigue Rsch Ctr, Univ of MI Hlth System-Lobby M, Ann Arbor, MI
Background/Purpose: Gout is the most treatable arthritis in the Western World and there are effective medications available to treat both acute episodes and chronic gout.…
Abstract Number: 159 • 2012 ACR/ARHP Annual Meeting
Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout
Michael A. Becker¹, Herbert S. B. Baraf², Robert A. Yood³, Aileen M. Dillon⁴, Janitzia Vazquez-Mellado⁵, Faith D. Ottery⁶, Dinesh Khanna⁷ and John S. Sundy⁸, ¹Medicine, University of Chicago, Chicago, IL, ²Arthritis & Rheumatism Associates, Wheaton, MD, ³Reliant Medical Group, Worcester, MA, ⁴Rheumatology Section, Kaiser Foundation Hospital, San Francisco, CA, ⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁶Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁷Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁸Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase conjugated to mPEG, was approved for use in refractory chronic gout in the US in 2010. The Phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].